Elinzanetant produced a reassuring safety profile in a pooled analysis of four randomized trials, with no liver toxicity or cancer signals reported across 52 weeks. The study also described mostly mild early side effects, supporting continued evaluation of the dual neurokinin receptor antagonist class for menopausal vasomotor symptoms.